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A B S T R A C T   
A series of lysine-based vinyl sulfone peptidomimetics were synthesised and evaluated for anti-trypanosomal 
activity against bloodstream forms of T. brucei. This focused set of compounds, varying in the P3 position, 
were accessed in a divergent manner from a common intermediate (ammonium salt 8). Several P3 analogues 
exhibited sub-micromolar EC50 values, with thiourea 14, urea 15 and amide 21 representing the most potent 
anti-trypanosomal derivatives of the series. In order to establish an in vitro selectivity index the most active anti- 
trypanosomal compounds were also assessed for their impact on cell viability and cytotoxity effects in 
mammalian cells. Encouragingly, all compounds only reduced cellular metabolic activity in mammalian cells to a 
modest level and little, or no cytotoxicity, was observed with the series.   
1. Introduction 
In 1992, it was reported that vinyl sulfones were inhibitors of the 
cysteine protease papain.1 Since then, compounds containing this 
functional group have emerged as valuable members of a toolkit of 
electrophilic agents (including, for example, maleimides etc.) with the 
ability to interact with and derivatise biological molecules.2 It is now 
well-appreciated that this occurs via the S-conjugate addition of vinyl 
sulfones with nucleophilic cysteine residues and, since Hanzlik’s initial 
report,1 several publications have appeared featuring the use of vinyl 
sulfone-based molecules as inhibitors of enzymes and chemical probes.3 
Efforts, most notably from the collective research groups of McKerrow, 
Rosenthal, Roush and Renslo,4 have identified thiophilic peptidyl vinyl 
sulfones 1 and 2 as lead structures to combat infections caused by 
parasitic organisms.5 HYPERLINK "SPS:refid::bib5" 
Specifically, regarding anti-parasitic activity, numerous studies have 
implicated trypanosomal cysteinyl proteases as targets for peptidyl vinyl 
sulfones.6 S-Derivatisation of these enzymes, which are critical to the 
survival of the bloodstream form of the parasite, leads to cell death.6–7 
We have developed a series of lysine-based compounds (e.g. 3, Figure 1) 
stemming from McKerrow’s previous work (e.g. 1 and 2) and have 
shown that members of this family exhibited potent anti-trypanosomal 
activity in vitro.8 To probe the P1′-P2 regions of the cysteinyl protease 
binding domain, a series of compounds with various substitutions at 
positions R2, R3 and R4 were prepared. However, to date, we have not 
similarly varied the identity of the Cbz substituent. This is of interest 
since substituents in this position protrude into the large P3 region of the 
cysteinyl protease7 binding pocket and in principle, additional binding 
interactions and/or selectivity might be achieved following optimisation 
of the group penetrating this region. With this in mind, it is important to 
note that the well-established methods for Cbz removal offer the possi-
bility to explore the P3 region from a common intermediate in a 
Abbreviations: Ac, acetyl; [α]D, specific rotation (measured at 589 nm); app, apparent; Ar, aromatic; Bu, butyl; Cbz, carboxybenzyl (benzyloxycarbonyl); d, 
doublet; dd, doublet of doublets; DIPEA, diisopropylethylamine; DMSO, dimethylsulfoxide; c-Hex, cyclohexane; CI, confidence interval; clogP, calculated partition 
coefficient (log10); EC50, effective concentration half maximal; EDCI, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; ES, electrospray; Et, ethyl; EtOAc, ethyl ac-
etate; equiv, equivalent; g/mg, gram/milligram; GI50, growth inhibition half maximal; H, hour(s); HaCaT, human keratinocyte cells; HOBt, hydroxybenzotriazole; 
HRMS, high resolution mass spectrometry; IR, infrared (spectroscopy); J, coupling constant; LD50, lethal dose half maximal; LDH, lactate dehydrogenase; M, molarity 
(moldm− 3); m, multiplet; Me, methyl; mL/μL, millilitre/microlitre; M.p, melting point; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NMR, 
nuclear magnetic resonance; Ph, phenyl; ppm, parts per million; q, quartet; Rf, retention factor; rt, room temperature (approx. 18 ◦C); S.D, standard deviation; t, 
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divergent manner. 
Previous approaches to access P3 substituted analogues of vinyl 
sulfone inhibitors (of the type 6) involve coupling strategies whereby an 
amino acid derivative (4) and vinyl sulfone ammonium salt (5) are 
united, whereby the desired P3 substituent (R1) is pre-installed (Scheme 
1).3a,4a,h,i Whilst convergent, from the perspective of rapidly identifying 
an ideal P3 substituent, this approach is limited. 
Previously, we have investigated the Cbz-deprotection of ε-amino 
naphthalene sulfonamide 7, a compound which itself exhibited prom-
ising anti-trypanosomal activity.8 Treatment of 7 with HBr in acetic acid 
gave ammonium bromide salt 8 which was isolated and was fully 
characterised. Upon treatment with just base 8 gradually underwent a 
diastereoselective intramolecular N-conjugate addition, forming 6- 
membered ring adduct 9 in moderate yield.8b Although 8 forms 9 in 
the absence of external electrophiles, the cyclisation took 24 h to reach 
completion. We, therefore, felt that ammonium salt 8 potentially offered 
a means to access P3 modified vinyl sulfone inhibitors of the type 10. In 
the current work, attempts to improve activity of our lead vinyl sulfone 
compound 7 involving treatment of 8 with a variety of electrophiles and 
subsequent biological evaluation of the resultant analogues, is reported. 
2. Chemistry 
In order to probe if ammonium salts, such as 8, would undergo the 
planned derivatisation, a test reaction sequence was performed using 
compound 11 (Scheme 2). Standard HBr-Cbz deprotection, followed by 
direct treatment of the resultant ammonium bromide salt with an aro-
matic isothiocyanate,9 in the presence of base, led to the isolation of 
thiourea 12 in reasonable yield. 
Based on this promising result, the similar synthesis of P3 analogues 
of compound 7 was considered. As shown in Scheme 3, thioureas 13, 14 
were accessed following the reaction of ammonium salt 8 with the 
corresponding isothiocyanates. Identical use of isocyanates gave com-
pounds 15 to 17 and we considered that established physicochemical 
differences between the thiourea and urea functional groups would be of 
interest.10 Alternatively, N-methyl piperazine and morpholine ureas 18 
and 19 were accessed in one-pot using initially carbonyldiimidazole and 
subsequently the respective cyclic secondary amines.11 This type of P3- 
interacting substituents are found in K777 (1) and K11002 (2) (see 
Figure 1) and served to provide an interesting comparison with the 
lysine derived vinyl sulfone inhibitors in our series.4 Attempts to syn-
thesise the corresponding thioureas using 1,1′-thiocarbonyldiimidazole, 
under otherwise identical conditions, were unsuccessful. Reaction of 8 
with tosyl chloride gave the sulfonamide analogue 20. Amide 21 was 
accessed from the substituted benzoyl chloride, whereas amides 22 and 
23 were prepared following EDCI based couplings, derivatives chosen to 
resemble P3 substituents recently reported.4h,j Overall, as shown in 
Scheme 3, resulting yields indicated that these reactions were inefficient 
with the accompanied production of side-products, including piper-
azinone 9. However, all analogues, 13 to 23, were isolated with high 
chemical purity. 
Azide analogue, 25, was synthesised using the diazo-transfer pro-
cedure reported by Goddard-Borger and co-workers.12 This reaction 
proved problematic, again, due to competing intramolecular cyclisation 
forming 9; nevertheless, 25 could be isolated in modest yield. From 25, 
peptidomimetic13 triazoles 26 and 27 were accessed using Click chem-
istry (Scheme 4).14–15 
3. Biology 
Using a previously reported method,16 T. b. brucei cells were 
Fig. 1. K777(1) and K11002 (2): Benchmark vinyl sulfone inhibitors and our 
lysine-based scaffold 3. 
Scheme 1. Traditional approach to P3 substituted vinyl sulfone inhibitor of type 6. Cbz deprotection/intramolecular cyclisation sequence and proposed intermo-
lecular functionalisation. 
Scheme 2. Sequential vinyl sulfone-Cbz-deprotection-thiourea formation: 
Synthesis of 12. 
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incubated with varying concentrations of each compound in the series 
and assessed for their ability to disrupt the life-cycle of trypanosomes via 
a standard Alamar Blue assay (Table 1).8,16 As shown in Entry 1, com-
pound 7 has an EC50 value of 0.74 μM and is the figure used as a 
benchmark for values determined in the current work. Interestingly, the 
ammonium salt 8, lacking the carbamate P3 substituent, possessed some 
activity (Entry 2). This was a somewhat unexpected finding since it was 
expected that the ammonium salt would be too polar for efficient 
cellular uptake. Unsurprisingly, the secondary cyclic amine 9, resulting 
from a diastereoselective intramolecular N-conjugate addition, conse-
quently lacking the vinyl sulfone motif, exhibits only negligible anti- 
trypanosomal activity (Entry 3). Thioureas 12–14, in contrast, exhibi-
ted sub-micromolar activity with the additional lipophilicity, conferred 
through inclusion of a para-trifluoromethyl group, providing slightly 
enhanced anti-trypanosomal activity (Entries 4 to 6). Moving from the 
P3 thiourea substituents to their urea counterparts, urea 15 proved 
slightly more active than the corresponding thioureas (Entry 7). As 
Entries 8 and 9 indicate, in comparison, t-butyl and n–butyl urea de-
rivatives, 16 and 17, are less active (significantly so in the case of 16). N- 
Methyl piperazine 18 and morpholine 19 derivatives, synthesised to 
mimic K777 (1) and K11002 (2), were also active producing EC50 values 
of 1.19 μM and 0.90 μM respectively (Entries 10 and 11). However, these 
compounds display reduced activity compared to their less substituted, 
secondary urea analogues. Sulfonamide 20 is active (Entry 12) with an 
EC50 value of 0.99 μM but again this figure is higher than observed for 
the secondary urea and thioureas (Entries 4–7 and 9). In contrast, tri-
fluoromethyl substituted amide 21 (Entry 13) exhibited an EC50 of 0.24 
μM, a value which is approximately equipotent to the most active ureas – 
compounds 14 and 15. 
As Entries 14 and 15 indicate, isonicotinamide 22 and 1,3-dioxane 
23 are active but slightly less active than 21. Interestingly, Garcia- 
Salcedo et al. have recently shown that nicotinamide itself inhibits the 
lysosomal cathepsin b-like protease, blocking endocytosis and thereby 
causing trypanosomal cell death at millimolar concentrations.17 Azide 
25, a more lipophilic analogue of ammonium salt 8 shows reduced ac-
tivity at > 5 μM (Entry 16), compared with an EC50 for the ammonium 
salt 8 of 3.43 μM (Entry 2). Triazoles 26 and 27, designed to protrude 
lipophilic aryl and alkyl chains into the putative P3 region of this com-
pound class’ biological target, are slightly more active than 25 but less 
active than ureas 14, 15, and also amide 21, possessing one, or two H- 
bond donors, and a (thio)carbonyl H-bond acceptor group (Entries 17 
and 18). Representative dose–response curves for the survival of T. b. 
brucei cells with vinyl sulfones 12, 14, 15, 18 and 21 are shown in 
Figure 2. 
Scheme 3. Thiourea, urea, sulfonamide and amide based P3 derivatives 13–23 [Conditions: aIsothiocyanate, Et3N, CH2Cl2, rt, 1–2 h; bIsocyanate, Et3N, CH2Cl2, rt, 
5–18 h; cCDI, Et3N, CH2Cl2, 40 ◦C, 1 h; then amine, 40 ◦C, 1 h; dTsCl, Et3N, CH2Cl2, rt, 1 h; eArCOCl, Et3N, CH2Cl2, rt, 18 h; fArCO2H, EDCI⋅HCl, HOBt⋅H2O, iPr2EtN, 
CH2Cl2, rt, 18 h]. 
Scheme 4. Azide 25 and triazole based analogues 26 and 27.  
Table 1 
Anti-trypanosomal activity for P3 analogues of lead vinyl sulfone 7.  
Entry Compound EC50 (μM)a 95% CI for the clogPc 
EC50 (μM)b 
1 7 0.74d ND 6.98 (±0.72) 
2 8 3.43 3.27 to 3.61 4.52 (±0.59)e 
3 9 >5 ND 3.90 (±0.56)e 
4 12 0.39 0.24 to 0.63 7.16 (±0.72) 
5 13 0.48 0.3 to 0.75 6.14 (±0.65) 
6 14 0.22 0.15 to 0.33 7.15 (±0.69) 
7 15 0.15 0.09 to 0.25 6.36 (±0.65) 
8 16 >5 ND 5.46 (±0.66) 
9 17 0.64 0.43 to 0.95 5.83 (±0.66) 
10 18 1.19 0.69 to 2.02 4.94 (±0.70)e 
11 19 0.90 0.75 to 1.08 4.51 (±0.69) 
12 20 0.99 0.80 to 1.25 6.68 (±0.64) 
13 21 0.24 0.18 to 0.32 7.22 (±0.75) 
14 22 0.71 0.53 to 0.96 4.99 (±0.74)e 
15 23 0.80 0.64 to 1.02 6.36 (±0.71) 
16 25 >5 ND 5.45 (±0.59) 
17 26 1.12 0.97 to 1.31 6.62 (±0.69) 
18 27 1.05 0.96 to 1.16 7.98 (±0.68)  
a Response of T. b. brucei (2 × 105 cells/mL) to exposure of varying concen-
trations of each compound determined by non-linear regression analysis of 
curve-fitting using the equation Y = 100/[1 + 10̂(logEC50-X) *Hill slope] and 
variable slope (four parameter) 
b CI = Confidence Interval. 
c Calculated using ACDlabs/ChemSketch (Freeware). 
d Value taken from Ref. 8b. 
e Value for free amine. ND = Not Determined. 
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The behaviour of compounds (12, 14, 15, 18 and 21) were investi-
gated in a human skin keratinocyte cell line (HaCaT) in order to assess 
the effects these compounds had on cell proliferation (GI50) and cyto-
toxicity (LC50). 
Figure 3 highlights that using the lactate dehydrogenanse (LDH) 
assay18 only negligible cytotoxicity was observed for the selected, more 
active compounds from the vinyl sulfone series. Encouragingly, only 
modest cytotoxicity can be seen at concentrations significantly higher 
than those required to kill trypanosomes (i.e. only at 100 μM). It should 
be mentioned that at this concentration compounds typically began to 
precipitate from solution and accordingly accurate LC50 figures could 
not be calculated. 
Using the MTT assay19 the effect of compounds 12, 14, 15, 18 and 21 
on cell proliferation were studied. As shown in the electronic supporting 
information (Figure S1) only data from compound 18, containing the N- 
methyl piperazine, fitted a typical sigmoid dose–response curve 
enabling an accurate GI50 (28.67 ± 9.75 μM) to be calculated. This effect 
on growth can be compared to the anti-trypanosomal EC50 value of 1.19 
μM. Other compounds demonstrated EC50 values in the range of 0.15 to 
0.39 mM in the whole-cell parasite assay (see Table 1) and only inhibited 
cell growth by approximately 20% at concentrations above 10 μM in the 
MTT assay, i.e. approximately a 25 fold selectivity window. As observed 
in the LDH assay activities above 100 µM could not be measured due to 
issues with compound solubility at these concentrations. Taken together 
the findings from the LDH and MTT assays indicate that our compounds 
may only inhibit mammalian cell growth rather than being intrinsically 
cytotoxic. 
4. Conclusion 
In conclusion we have disclosed results for a series of P3 modified 
phenylalanine-lysine containing vinyl sulfones. Although the chemical 
yields were moderate, a wide range of structurally and electronically 
diverse analogues of our previously prepared, most active compound 
have been accessed from one common intermediate. Over the sixteen- 
member vinyl sulfone dipeptide-based family, most of the structural 
changes to the P3 substituent were well tolerated in terms of anti- 
trypanosomal activity. However, optimum activity was observed for 
compounds with a lipophilic aromatic entity linked to the main vinyl 
sulfone dipeptide backbone with an H-bond donor: Secondary thiourea 
and urea analogues 12 to 15 and secondary trifluromethylbenzamide 
analogue 21. The calculated log octanol/water partition coefficient 
(clogP) illustrates that there is no obvious relationship between total 
compound lipophilicity and activity in this assay, however, in general 
terms, increasing the lipophilicity of substituents at P3 increases activity 
in the in vitro assays. Importantly, some members of the series (e.g. 
compound 12) exhibited not only potent activity against trypanosomes 
but also high selectivity compared with the immortal keratinocyte cell 
line – HaCaT, and establishes the precident for further development of 
the series as anti-trypanosomal leads.20 
5. Experimental 
5.1. General experimental 
1H, 13C and 19F NMR spectra were recorded on Varian Unity 500 
MHz and 400 MHz system spectrometers and coupling constants (J) are 
quoted in Hertz. High resolution mass spectra were carried out on a 
Waters/Micromass LCT ESI mass spectrometer in the electrospray pos-
itive (ES+) mode with a time-of-flight analyser. Reported, experimen-
tally found values are all within ± 5 ppm from the calculated values. 
Infrared spectra were recorded on a Varian Instruments Excalibur series 
FT-IR 3100 spectrometer. Melting points were recorded on a Gallen-
kamp electrothermal melting point apparatus. Optical rotation data was 
obtained with a Perkin Elmer Model 343 polarimeter and values are 
quoted in units of 10-1degcm2g− 1. Reagents were obtained from com-
mercial suppliers and were used without further purification. Thin-layer 
chromatography was performed on silica coated aluminium sheets and 
compounds were visualised with UV light and aqueous potassium per-
manganate, followed by heating. Ammonium bromide 8 was synthesised 




A 33% solution of HBr in AcOH (1 mL) was added to a stirred solu-
tion of vinyl sulfone 11 (27 mg, 0.03 mmol, 1 equiv.) in CH2Cl2 (1 mL) at 
0 ◦C. The reaction mixture was stirred for 2 h warming slowly to rt. 
Solvent was removed in vacuo to give the crude product which was 
redissolved in CH2Cl2 (0.5 mL), precipitated with Et2O (20 mL). The 
suspension was allowed to settle and the supernatant was removed by 
Pasteur pippette. The product was dried under high vaccuum to give the 
ammonium salt as a pink powder. In the same vessel, 4-(trifluoromethyl) 
phenyl isothiocyanate (7 mg, 0.03 mmol, 1.1 equiv.) was added fol-
lowed by CH2Cl2 (1 mL) and the mixture was stirred. Et3N (18 μL, 0.13 
mmol, 4 equiv.) was then added and the mixture was left to stir over-
night at room temperature. Solvent was removed in vacuo to give the 
crude product. Purification by column chromatography (c-Hex/EtOAc; 
1:1) gave thiourea 12 (20 mg, 69%) as an off white solid. M.p. =















15 [0.144 ± 0.048]
12 [0.410 ± 0.124]
14 [0.220 ± 0.035]
21 [0.242 ± 0.007]
18 [1.184 ± 0.300]
IC50 Mean ± SD ( M)
Fig. 2. Representative dose-response curves for T. b. brucei (2 × 105 cells/mL) 
on exposure to varying concentrations of compounds 12, 14, 15, 18 and 21. 
The values represent the mean ± S.D. for two independent experiments per-
formed in triplicate. 




















Fig. 3. Determination of cytoxicity via the lactate dehydrogenase (LDH) assay. 
Data are expressed as percentage of LDH release compared with the positive 
control. Each bar represents the mean ± S.D. of triplicate determinations from 
three independent experiments. 
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94–99 ◦C. Rf = 0.3 (c-Hex/EtOAc; 1:1). IR (film): νmax = 3320, 3061, 
2936, 1661, 1617, 1525, 1503, 1439, 1360, 1325, 1262, 1216, 1148, 
1116, 1086, 1067, 1024 cm− 1. 1H NMR (400 MHz, CDCl3): δ =
1.20–1.67 (m, 6H, CH2) 2.79–2.90 (m, 2H, CH2) 3.13 (dd, J = 14.0, 8.0 
Hz, 1H, CH2) 3.24 (dd, J = 14.0, 7.0 Hz, 1H, CH2) 3.92 (s, 3H, CH3) 3.94 
(s, 3H, CH3) 4.66–4.77 (m, 1H, CH) 5.28 (app. q, J = 7.5 Hz, 1H, CH) 
5.84 (t, J = 6.0 Hz, 1H, NH) 6.10 (dd, J = 15.0, 2.0 Hz, 1H, CH) 6.65 (d, 
J = 9.0 Hz, 1H, NH) 6.81 (dd, J = 15.0, 4.0 Hz, 1H, CH) 6.99 (d, J = 7.5 
Hz, 1H, NH) 7.15 (s, 1H, ArH) 7.18–7.25 (m, 5H, ArH) 7.33 (d, J = 8.5 
Hz, 2H, ArH) 7.51 (d, J = 8.5 Hz, 2H, ArH) 7.54 (s, 1H, ArH) 7.57 (d, J =
8.0 Hz, 2H, ArH) 7.62–7.67 (m, 1H, ArH) 7.84 (d, J = 7.0 Hz, 2H, ArH) 
8.58 (s, 1H, NH) ppm. 13C NMR (100 MHz, CDCl3): δ = 21.6 (CH2) 27.4 
(CH2) 33.1 (CH2) 37.3 (CH2) 42.0 (CH2) 48.6 (CH) 56.5 (CH3) 56.6 
(CH3) 59.6 (CH) 111.2 (C) 113.9 (CH) 117.2 (CH) 123.5 (CH) 123.9 (q, 
JCF = 272.0 Hz, CF3) 126.5 (q, JCF = 3.5 Hz, CH) 127.3 (CH) 127.5 (q, 
JCF = 32.0 Hz, C) 127.7 (CH) 128.9 (CH) 129.2 (CH) 129.3 (CH) 129.4 
(C) 130.4 (CH) 133.6 (CH) 136.1 (C) 139.9 (C) 140.4 (C) 145.5 (CH) 
148.1 (C) 152.6 (C) 171.2 (CO) 180.2 (CS) ppm. 19F NMR (376 MHz, 
CDCl3): δ = -62.39 ppm. HRMS (ES+) C38H40N4O7NaBrF3S3 (MNa+) 
calcd. 919.1092; found 919.1069. [α]D = -26 (c = 0.1, CH2Cl2). 
5.3. (S)-N-((S,E)-7-(Naphthalene-1-sulfonamido)-1-(phenylsulfonyl) 
hept-1-en-3-yl)-3-phenyl-2-(3-phenylthioureido)propanamide 13 
Ammonium salt 8 (19 mg, 0.03 mmol, 1 equiv.) was stirred with 
phenyl isothiocyanate (13 μL, 0.11 mmol, 4 equiv.) in CH2Cl2 (1 mL). 
Et3N (15 μL, 0.11 mmol, 4 equiv.) was then added and the mixture was 
stirred for 1 h. Solvent was removed in vacuo to give the crude product. 
Purification by column chromatography (c-Hex/EtOAc; 1:1) gave thio-
urea 13 (7 mg, 34%) as a white solid. M.p. = 71–76 ◦C. Rf = 0.3 (c-Hex/ 
EtOAc; 1:1). IR (film): νmax = 3322, 2929, 1665, 1595, 1528, 1498, 
1447, 1315, 1145, 1085, 805, 741 cm− 1. 1H NMR (500 MHz, CDCl3): δ 
= 1.23–1.49 (m, 3H, CH2) 1.52–1.66 (m, 3H, CH2) 2.72–2.80 (m, 1H, 
CH2) 2.94–3.02 (m, 1H, CH2) 3.11 (dd, J = 14.0, 8.0 Hz, 1H, CH2) 3.18 
(dd, J = 14.0, 8.0 Hz, 1H, CH2) 4.60–4.67 (m, 1H, CH) 5.29 (app. q, J =
8.0 Hz, 1H, CH) 6.08 (dd, J = 15.0, 2.0 Hz, 1H, CH) 6.31 (t, J = 5.5 Hz, 
1H, NH) 6.49 (d, J = 8.5 Hz, 1H, NH) 6.79 (dd, J = 15.0, 4.0 Hz, 1H, CH) 
6.96 (d, J = 8.5 Hz, 1H, NH) 7.04 (d, J = 7.5 Hz, 2H, ArH) 7.18–7.29 (m, 
6H, ArH) 7.31–7.36 (m, 2H, ArH) 7.52–7.57 (m, 3H, ArH) 7.60–7.65 (m, 
2H, ArH) 7.70–7.74 (m, 1H, ArH) 7.83 (d, J = 7.0 Hz, 2H, ArH) 7.95 (d, 
J = 8.0 Hz, 1H, ArH) 8.08 (d, J = 8.0 Hz, 1H, ArH) 8.24 (dd, J = 7.5, 1.0 
Hz, 1H, ArH) 8.78 (s, 1H, NH) 8.87 (d, J = 8.5 Hz, 1H, ArH) ppm. 13C 
NMR (125 MHz, CDCl3): 22.1 (CH2) 28.6 (CH2) 32.2 (CH2) 36.5 (CH2) 
41.8 (CH2) 49.3 (CH) 59.1 (CH) 124.1 (CH) 124.6 (CH) 124.9 (CH) 
127.0 (CH) 127.3 (CH) 127.35 (CH) 127.7 (CH) 128.1 (C) 128.5 (CH) 
128.8 (CH) 129.0 (CH) 129.2 (CH) 129.3 (CH) 129.6 (CH) 130.1 (CH) 
130.2 (CH) 133.5 (CH) 134.2 (C) 134.25 (C) 134.3 (C) 135.7 (C) 136.0 
(C) 140.0 (C) 145.7 (CH) 170.8 (CO) 179.8 (CS) ppm. HRMS (ES+) 
C39H40N4O5NaS3 (MNa+) calcd. 763.2059; found 763.2085. [α]D = -52 




Ammonium salt 8 (22 mg, 0.03 mmol, 1 equiv.) was stirred with 4- 
(trifluoromethyl)phenyl isothiocyanate (12 mg, 0.06 mmol, 2 equiv.) in 
CH2Cl2 (1 mL). Et3N (12 μL, 0.09 mmol, 3 equiv.) was then added and 
the mixture was stirred for 2 h. Solvent was removed in vacuo to give the 
crude product. Purification by column chromatography (c-Hex/EtOAc; 
1:1) gave thiourea 14 (8 mg, 34%) as a white solid. M.p. = 96–101 ◦C. Rf 
= 0.7 (c-Hex/EtOAc; 1:2). IR (film): νmax = 3329, 3059, 2941, 1660, 
1616, 1527, 1447, 1324, 1146, 1067, 738 cm− 1. 1H NMR (400 MHz, 
CDCl3): δ = 1.32–1.64 (m, 6H, CH2) 2.78–2.92 (m, 2H, CH2) 3.20 (dd, J 
= 14.0, 8.5 Hz, 1H, CH2) 3.27 (dd, J = 14.0, 7.5 Hz, 1H, CH2) 4.66–4.76 
(m, 1H, CH) 5.34 (app. q, J = 8.0 Hz, 1H, CH) 5.95 (t, J = 5.5 Hz, 1H, 
NH) 6.03 (dd, J = 15.0, 2.0 Hz, 1H, CH) 6.67 (d, J = 9.0 Hz, 1H, NH) 
6.79 (dd, J = 15.0, 4.0 Hz, 1H, CH) 6.98 (d, J = 8.5 Hz, 1H, NH) 
7.19–7.29 (m, 6H, ArH) 7.32 (d, J = 8.5 Hz, 2H, ArH) 7.52 (d, J = 8.5 
Hz, 2H, ArH) 7.53–7.59 (m, 2H, ArH) 7.61–7.67 (m, 2H, ArH) 7.73 (t, J 
= 7.5 Hz, 1H, ArH) 7.84 (d, J = 7.5 Hz, 2H, ArH) 7.97 (d, J = 8.0 Hz, 1H, 
ArH) 8.10 (d, J = 8.0 Hz, 1H, ArH) 8.21 (d, J = 7.5 Hz, 1H, ArH) 8.77 (d, 
J = 8.5 Hz, 1H, ArH) 8.80 (s, 1H, NH) ppm. 13C NMR (100 MHz, CDCl3): 
δ = 21.5 (CH2) 27.5 (CH2) 33.3 (CH2) 36.9 (CH2) 41.9 (CH2) 48.5 (CH) 
59.4 (CH) 123.7 (CH) 123.8 (q, JCF = 271.5 Hz, CF3) 124.1 (CH) 124.3 
(CH) 126.7 (q, JCF = 3.5 Hz, CH) 127.1 (CH) 127.4 (CH) 127.7 (CH) 
127.9 (q, JCF = 33.0 Hz, C-CF3) 128.0 (C) 128.6 (CH) 128.9 (CH) 129.2 
(2 × CH) 129.3 (CH) 129.7 (CH) 130.4 (CH) 133.6 (CH) 133.8 (C) 134.3 
(C) 134.5 (CH) 136.0 (C) 139.9 (C) 140.2 (C) 145.4 (CH) 171.2 (CO) 
180.2 (CS) ppm. 19F NMR (376 MHz, CDCl3): δ = -62.47 ppm. HRMS 
(ES+) C40H39N4O5F3NaS3 (MNa+) calcd. 831.1932; found 831.1948. 
[α]D = -36 (c = 0.1, CH2Cl2). 
5.5. (S)-N-((S,E)-7-(Naphthalene-1-sulfonamido)-1-(phenylsulfonyl) 
hept-1-en-3-yl)-3-phenyl-2-(3-phenylureido)propanamide 15 
Ammonium bromide salt 8 (29 mg, 0.04 mmol, 1 equiv.) was stirred 
with phenyl isocyanate (23 μL, 0.21 mmol, 5 equiv.) in CH2Cl2 (1 mL). 
Et3N (35 μL, 0.26 mmol, 6 equiv.) was added and the reaction mixture 
was stirred for 5 h after which time solvent was removed in vacuo. 
Purifcation by column chromatography (c-Hex/EtOAc; 2:1) gave urea 
15 (8 mg, 26%) as a white solid. M.p. = 90–94 ◦C. Rf = 0.4 (c-Hex/ 
EtOAc; 1:2). IR (film): νmax = 3291, 3058, 2922, 2860, 1648, 1599, 
1551, 1499, 1444, 1315, 1264, 1234, 1145, 1085, 1026, 805 cm− 1. 1H 
NMR (400 MHz, CDCl3): δ = 1.16–1.44 (m, 6H, CH2) 2.60–2.70 (m, 1H, 
CH2) 2.88–2.98 (m, 1H, CH2) 3.06–3.18 (m, 2H, CH2) 4.43–4.54 (m, 1H, 
CH) 4.99–5.12 (m, 1H, CH) 5.96 (dd, J = 15.0, 1.5 Hz, 1H, CH) 6.23 (d, 
J = 9.0 Hz, 1H, NH) 6.65 (dd, J = 15.0, 5.0 Hz, 1H, CH) 6.89 (s (br), 1H, 
NH) 6.97 (t, J = 7.5 Hz, 1H, ArH) 7.16–7.22 (m, 3H, NH, ArH) 7.23–7.30 
(m, 5H, NH, ArH) 7.35 (d, J = 8.0 Hz, 2H, ArH) 7.51–7.57 (m, 4H, ArH) 
7.59–7.65 (m, 2H, ArH) 7.66–7.70 (m, 1H, ArH) 7.82 (m, 2H, ArH) 7.95 
(d, J = 7.5 Hz, 1H, ArH) 8.08 (d, J = 8.0 Hz, 1H, ArH) 8.21 (dd, J = 7.5, 
1.5 Hz, 1H, ArH) 8.76 (d, J = 8.5 Hz, 1H, ArH) ppm. 13C NMR (100 MHz, 
CDCl3) δ = 22.1 (CH2) 28.6 (CH2) 32.8 (CH2) 39.5 (CH2) 42.2 (CH2) 49.0 
(CH) 55.0 (CH) 120.0 (CH) 123.4 (CH) 124.1 (CH) 124.6 (CH) 127.05 
(CH) 127.15 (CH) 127.7 (CH) 128.1 (C) 128.5 (CH) 128.8 (CH) 129.0 
(CH) 129.05 (CH) 129.1 (CH) 129.3 (CH) 129.4 (CH) 130.2 (CH) 133.5 
(CH) 134.2 (CH) 134.3 (C) 134.5 (C) 136.4 (C) 138.5 (C) 140.2 (C) 145.7 
(CH) 155.8 (CO) 173.5 (CO) ppm. HRMS (ES+) C39H40N4O6NaS2 
(MNa+) calcd. 747.2287; found 747.2315. [α]D = -27 (c = 0.1, CH2Cl2). 
5.6. (S)-2-(3-(tert-Butyl)ureido)-N-((S,E)-7-(naphthalene-1- 
sulfonamido)-1-(phenylsulfonyl)hept-1-en-3-yl)-3-phenylpropanamide 16 
Ammonium salt 8 (20 mg, 0.03 mmol, 1 equiv.) was stirred with tert- 
butyl isocyanate (7 μL, 0.06 mmol, 2 equiv.) in CH2Cl2 (1 mL). Et3N (12 
μL, 0.09 mmol, 3 equiv.) was added and the mixture was left to stir 
overnight. Solvent was removed in vacuo and the crude product was 
purified by column chromatography (c-Hex/EtOAc; 1:1) which gave 
urea 16 (11 mg, 54%) as a white solid. M.p. = 69–74 ◦C. Rf = 0.4 (c-Hex/ 
EtOAc; 1:2). IR (film): νmax = 3320, 2921, 1717, 1642, 1549, 1453, 
1307, 1211, 1146, 1086 cm− 1. 1H NMR (400 MHz, CDCl3): δ =
1.19–1.59 (m, 15H, tBu, CH2) 2.66–2.74 (m, 1H, CH2) 2.94–3.23 (m, 3H, 
CH2) 4.63–4.82 (m, 2H, CH) 5.09 (s, 1H, NH) 5.63 (d, J = 9.0 Hz, 1H, 
NH) 6.02 (d, J = 15.0 Hz, 1H, CH) 6.15 (s (br), 1H, NH) 6.79 (dd, J =
15.0, 4.0 Hz, 1H, CH) 7.02 (s (br), 1H, NH) 7.11–7.35 (m, 5H, ArH) 
7.46–7.75 (m, 6H, ArH) 7.83 (d, J = 8.0 Hz, 2H, ArH) 7.95 (d, J = 8.0 
Hz, 1H, ArH) 8.07 (d, J = 8.0 Hz, 1H, ArH) 8.20 (d, J = 7.0 Hz, 1H, ArH) 
8.73 (d, J = 8.5 Hz, 1H, ArH) ppm. 13C NMR (100 MHz, CDCl3): δ = 22.3 
(CH2) 27.1 (CH2) 29.3 (CH3) 33.3 (CH2) 37.7 (CH2) 42.2 (CH2) 47.8 
(CH) 50.5 (C) 55.0 (CH) 124.1 (CH) 124.5 (CH) 126.8 (CH) 127.0 (CH) 
127.7 (CH) 128.1 (C) 128.5 (CH) 128.7 (CH) 129.2 (CH) 129.3 (CH) 
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129.4 (CH) 129.5 (CH) 130.3 (CH) 133.5 (CH) 134.2 (CH) 134.3 (C) 
134.5 (C) 137.0 (C) 140.1 (C) 146.0 (CH) 157.4 (CO) 174.0 (CO) ppm. 
HRMS (ES+) C37H44N4O6NaS2 (MNa+) calcd. 727.2600; found 
727.2607. [α]D = -5 (c = 0.1, CH2Cl2). 
5.7. (S)-2-(3-Butylureido)-N-((S,E)-7-(naphthalene-1-sulfonamido)-1- 
(phenylsulfonyl)hept-1-en-3-yl)-3-phenylpropanamide 17 
Ammonium bromide salt 8 (27 mg, 0.04 mmol, 1 equiv.) was stirred 
with n-butyl isocyanate (20 μL, 0.17 mmol, 4 equiv.) in CH2Cl2 (1 mL). 
Et3N (24 μL, 0.17 mmol, 4 equiv.) was added and the mixture was left to 
stir overnight. Solvent was removed in vacuo to give the crude product 
which was purified by column chromatography (c-Hex/EtOAc; 1:1) 
giving urea 17 (6 mg, 22%) as a white solid. M.p. = 76–82 ◦C. Rf = 0.3 
(c-Hex/EtOAc; 1:1). IR (film): νmax = 3308, 2956, 2932, 2863, 1638, 
1561, 1509, 1447, 1307, 1145, 1085, 981 cm− 1. 1H NMR (400 MHz, 
CDCl3): δ = 0.88 (t, J = 7.5 Hz, 3H, CH3) 1.24–1.38 (m, 6H, CH2) 
1.39–1.55 (m, 4H, CH2) 2.71–2.80 (m, 1H, CH2) 2.88–3.00 (m, 1H, CH2) 
3.01–3.19 (m, 4H, CH2) 4.60–4.77 (m, 2H, CH) 5.27 (s, 1H, NH) 5.62 (s, 
1H, NH) 5.96 (d, J = 15.0 Hz, 1H, CH) 6.43 (s (br), 1H, NH) 6.77 (dd, J 
= 15.0, 4.0 Hz, 1H, CH) 6.89 (s (br), 1H, NH) 7.10–7.24 (m, 5H, ArH) 
7.51–7.58 (m, 3H, ArH) 7.59–7.65 (m, 2H, ArH) 7.68 (t, J = 8.0 Hz, 1H, 
ArH) 7.83 (d, J = 7.5 Hz, 2H, ArH) 7.94 (d, J = 8.0 Hz, 1H, ArH) 8.06 (d, 
J = 8.0 Hz, 1H, ArH) 8.20 (d, J = 7.5 Hz, 1H, ArH) 8.74 (d, J = 8.5 Hz, 
1H, ArH) ppm. 13C NMR (100 MHz, CDCl3): δ = 13.9 (CH3) 20.1 (CH2) 
21.5 (CH2) 27.7 (CH2) 32.1 (CH2) 33.5 (CH2) 38.6 (CH2) 40.5 (CH2) 42.3 
(CH2) 48.3 (CH) 55.7 (CH) 124.3 (CH) 124.7 (CH) 127.05 (CH) 127.1 
(CH) 127.8 (CH) 128.3 (C) 128.5 (CH) 128.7 (CH) 129.2 (CH) 129.3 
(CH) 129.4 (CH) 129.5 (CH) 130.2 (CH) 133.6 (CH) 134.3 (CH) 134.5 
(C) 134.9 (C) 137.0 (C) 140.3 (C) 146.2 (CH) 158.4 (CO) 173.5 (CO) 
ppm. HRMS (ES+) C37H44N4O6NaS2 (MNa+) calcd. 727.2600; found 




In a small screw cap vial, ammonium salt 8 (25 mg, 0.04 mmol, 1 
equiv.) was stirred in CH2Cl2 (0.5 mL). Et3N (6 μL, 0.04 mmol, 1.1 
equiv.) was added followed by carbonyldiimidazole (7 mg, 0.04 mmol, 
1.1 equiv.). The reaction mixture was then warmed with a water bath to 
40 ◦C for 1 h. N-Methyl piperazine (5 μL, 0.04 mmol, 1.2 equiv.) was 
then added and stirring continued at 40 ◦C for 1 h. Direct purification by 
column chromatography (CH2Cl2/MeOH; 15:1) gave urea 18 (15 mg, 
56%) as a white solid. M.p. = 69–75 ◦C. Rf = 0.3 (CH2Cl2/MeOH; 10:1). 
IR (film): νmax = 3270, 3060, 2940, 2863, 2800, 1657, 1625, 1533, 
1446, 1412, 1306, 1264, 1239, 1201, 1145, 1085, 1001, 805 cm− 1. 1H 
NMR (500 MHz, CDCl3): δ = 1.17–1.37 (m, 4H, CH2) 1.39–1.51 (m, 2H, 
CH2) 2.28 (s, 3H, CH3) 2.29–2.34 (m, 2H, CH2) 2.35–2.43 (m, 2H, CH2) 
2.75–2.81 (m, 1H, CH2) 2.95–3.04 (m, 1H, CH2) 3.09 (dd, J = 13.5, 8.0 
Hz, 1H, CH2) 3.17 (dd, J = 13.5, 7.5 Hz, 1H, CH2) 3.31–3.38 (m, 2H, 
CH2) 3.39–3.46 (m, 2H, CH2) 4.56 (app. q, J = 8.0 Hz, 1H, CH) 
4.61–4.69 (m, 1H, CH) 5.60 (d, J = 8.0 Hz 1H, NH) 5.98–6.03 (m, 1H, 
NH) 6.10 (dd, J = 15.0, 2.0 Hz, 1H, CH) 6.74 (dd, J = 15.0, 4.0 Hz, 1H, 
CH) 6.78 (d, J = 9.5 Hz, 1H, NH) 7.15–7.25 (m, 5H, ArH) 7.52–7.58 (m, 
4H, ArH) 7.62–7.69 (m, 2H, ArH) 7.85 (d, J = 7.0 Hz, 2H, ArH) 7.92 (d, 
J = 8.0 Hz, 1H, CH) 8.06 (d, J = 8.0 Hz, 1H, CH) 8.23 (dd, J = 7.5, 1.0 
Hz, 1H, CH) 8.78 (d, J = 8.5 Hz, 1H, CH) ppm. 13C NMR (125 MHz, 
CDCl3): δ = 22.1 (CH2) 27.2 (CH2) 32.2 (CH2) 37.4 (CH2) 42.2 (CH2) 
43.8 (CH2) 46.0 (CH3) 47.9 (CH) 54.5 (CH2) 56.1 (CH) 124.2 (CH) 124.6 
(CH) 126.9 (CH) 127.0 (CH) 127.7 (CH) 128.1 (C) 128.2 (CH) 128.7 
(CH) 129.15 (CH) 129.25 (CH) 129.32 (2 × CH) 130.2 (CH) 133.5 (CH) 
134.1 (CH) 134.3 (C) 135.1 (C) 137.0 (C) 140.1 (C) 145.8 (CH) 157.5 
(CO) 173.3 (CO) ppm. HRMS (ES+) C38H45N5O6NaS2 (MNa+) calcd. 




In a small screw cap vial, ammonium salt 8 (21 mg, 0.03 mmol, 1 
equiv.) was stirred in CH2Cl2 (0.5 mL). Et3N (5 μL, 0.04 mmol, 1.2 
equiv.) was added followed by carbonyldiimidazole (8 mg, 0.04 mmol, 
1.2 equiv.). The reaction mixture was then warmed with a water bath to 
40 ◦C for 1 h. Morpholine (3 μL, 0.04 mmol, 1.2 equiv.) was then added 
and stirring continued at 40 ◦C for 1 h. The reaction mixture was then 
purified directly by column chromatography (EtOAc) to give urea 19 
(12 mg, 55%) as a white solid. M.p. = 74–78 ◦C. Rf = 0.3 (EtOAc). IR 
(film): νmax = 3270, 3065, 2927, 2859, 1661, 1625, 1535, 1446, 1305, 
1262, 1145, 1118, 1085, 994 cm− 1. 1H NMR (500 MHz, CDCl3): δ =
1.22–1.41 (m, 4H, CH2) 1.43–1.55 (m, 2H, CH2) 2.75–2.81 (m, 1H, CH2) 
2.97–3.06 (m, 1H, CH2) 3.13 (dd, J = 14.0, 8.0 Hz, 1H, CH2) 3.21 (dd, J 
= 14.0, 7.5 Hz, 1H, CH2) 3.31 (ddd, J = 13.0, 6.5, 3.5 Hz, 2H, CH2) 3.40 
(ddd, J = 13.0, 6.5, 3.5 Hz, 2H, CH2) 3.59 (ddd, J = 11.5, 6.5, 3.5 Hz, 
2H, CH2) 3.66 (ddd, J = 11.5, 6.5, 3.5 Hz, 2H, CH2) 4.53 (app. q, J = 8.0 
Hz, 1H, CH) 4.68–4.76 (m, 1H, CH) 5.66 (d, J = 8.0 Hz, 1H, NH) 5.71 
(dd, J = 8.0, 2.5 Hz, 1H, NH) 6.14 (dd, J = 15.0, 2.0 Hz, 1H, CH) 6.65 (d, 
J = 9.5 Hz, 1H, NH) 6.77 (dd, J = 15.0, 4.0 Hz, 1H, CH) 7.16–7.28 (m, 
5H, ArH) 7.51–7.60 (m, 4H, ArH) 7.63–7.67 (m, 1H, ArH) 7.68–7.73 (m, 
1H, ArH) 7.86 (d, J = 7.0 Hz, 2H, ArH) 7.93 (d, J = 8.0 Hz, 1H, ArH) 
8.07 (d, J = 8.0 Hz, 1H, ArH) 8.23 (dd, J = 7.5,1.0 Hz, 1H, ArH) 8.77 (d, 
J = 8.5 Hz, 1H, ArH) ppm. 13C NMR (125 MHz, CDCl3): δ = 20.8 (CH2) 
27.0 (CH2) 33.2 (CH2) 37.2 (CH2) 42.2 (CH2) 44.1 (CH2) 47.7 (CH) 56.1 
(CH) 66.5 (CH2) 124.2 (CH) 124.5 (CH) 126.9 (CH) 127.0 (CH) 127.7 
(CH) 128.1 (C) 128.2 (CH) 128.7 (CH) 129.19 (CH) 129.24 (CH) 129.27 
(CH) 129.33 (CH) 130.3 (CH) 133.5 (CH) 134.2 (CH) 134.3 (C) 134.9 
(C) 137.0 (C) 140.1 (C) 145.7 (CH) 157.7 (CO) 173.3 (CO) ppm. HRMS 
(ES+) C37H42N4O7NaS2 (MNa+) calcd. 741.2393; found 741.2427. [α]D 
= -16 (c = 0.1, CH2Cl2). 
5.10. (S)-2-(4-Methylphenylsulfonamido)-N-((S,E)-7-(naphthalene-1- 
sulfonamido)-1-(phenylsulfonyl)hept-1-en-3-yl)-3-phenylpropanamide 20 
Ammonium salt 8 (32 mg, 0.05 mmol, 1 equiv.) was stirred with 4- 
toluenesulfonyl chloride (41 mg, 0.22 mmol, 5 equiv.) in CH2Cl2 (1 
mL). Et3N (30 μL, 0.22 mmol, 5 equiv.) was then added and the reaction 
mixture was stirred for 1 h. Solvent was removed in vacuo to give the 
crude product. Direct purifcation by column chromatography (c-Hex/ 
EtOAc; 1:1) gave sulfonamide 20 (14 mg, 40%) as a white solid. M.p. =
69–71 ◦C. Rf = 0.7 (c-Hex/EtOAc; 1:2). IR (film): νmax = 3336, 3060, 
2930, 2861, 1668, 1597, 1537, 1447, 1307, 1147, 1087, 956, 810, 734 
cm− 1. 1H NMR (500 MHz, CDCl3): δ = 1.21–1.57 (m, 6H, CH2) 2.39 (s, 
3H, CH3) 2.81 (dd, J = 14.0, 8.5 Hz, 1H, CH2) 2.83–2.94 (m, 2H, CH2) 
3.01 (dd, J = 14.0, 5.5 Hz, 1H, CH2) 3.80–3.86 (m, 1H, CH) 4.54–4.61 
(m, 1H, CH) 5.30 (t, J = 6.20, 1H, NH) 5.63 (d, J = 6.5 Hz, 1H, NH) 6.51 
(dd, J = 15.0, 2.0 Hz, 1H, CH) 6.70 (d, J = 9.0 Hz, 1H, NH) 6.80 (dd, J =
15.0, 4.5 Hz, 1H, CH) 6.89 (d, J = 7.0, 2H, ArH) 7.04 (t, J = 7.5 Hz, 2H, 
ArH) 7.10 (d, J = 7.5 Hz, 1H, ArH) 7.12 (d, J = 8.0 Hz, 2H, ArH) 7.43 (d, 
J = 8.5 Hz, 2H, ArH) 7.53 (d, J = 7.5 Hz, 2H, ArH) 7.56 (d, J = 8.5 Hz, 
1H, ArH) 7.57–7.63 (m, 2H, ArH) 7.64–7.67 (m, 1H, ArH) 7.88 (d, J =
7.0 Hz, 2H, ArH) 7.95 (d, J = 8.0 Hz, 1H, ArH) 8.08 (d, J = 8.0 Hz, 1H, 
ArH) 8.25 (dd, J = 7.5, 1.0 Hz, 1H, ArH) 8.67 (d, J = 8.5 Hz, 1H, ArH) 
ppm. 13C NMR (125 MHz, CDCl3): δ = 21.6 (CH3) 21.8 (CH2) 28.5 (CH2) 
32.7 (CH2) 38.1 (CH2) 42.3 (CH2) 49.4 (CH) 58.2 (CH) 124.2 (CH) 124.3 
(CH) 127.0 (CH) 127.1 (2 × CH) 127.7 (CH) 128.1 (C) 128.5 (CH) 128.8 
(CH) 129.0 (CH) 129.2 (CH) 129.3 (CH) 129.6 (CH) 129.8 (CH) 130.5 
(CH) 133.4 (CH) 134.25 (C) 134.3 (CH) 134.6 (C) 135.3 (C) 135.35 (C) 
140.2 (C) 143.8 (C) 145.3 (CH) 170.5 (CO) ppm. HRMS (ES+) 
C39H41N3O7NaS3 (MNa+) calcd. 782.2004; found 782.2010. [α]D = -55 
(c = 0.1, CH2Cl2). 
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Ammonium salt 8 (30 mg, 0.04 mmol, 1 equiv.) was stirred with 4- 
(trifluoromethyl)benzoyl chloride (32 μL, 0.22 mmol, 5 equiv.) in 
CH2Cl2 (1 mL). Et3N (37 μL, 0.26 mmol, 6 equiv.) was then added and 
the reaction mixture was left to stir overnight. The reaction mixture was 
diluted with CH2Cl2 (10 mL) and washed with water (5 mL). The 
aqueous layer was extracted with CH2Cl2 (2 × 5 mL). The combined 
organic layers were washed with brine (5 mL), dried over MgSO4, 
filtered and solvent was removed in vacuo. The crude residue was pu-
rified by column chromatography (c-Hex/EtOAc; 1:1) to give amide 21 
(11 mg, 32%) as a white solid. M.p. = 159–161 ◦C. Rf = 0.5 (c-Hex/ 
EtOAc; 1:2). IR (film): νmax = 3287, 2926, 1699, 1661, 1643, 1537, 
1446, 1324, 1260, 1134, 1065, 847, 808, 754 cm− 1. 1H NMR (400 MHz, 
CDCl3/CD3OD 3:2, CD3OD reference): δ = 1.09–1.48 (m, 6H, CH2) 
2.70–2.87 (m, 2H, CH2) 3.03 (dd, J = 13.5, 7.0 Hz, 1H, CH2) 3.11 (dd, J 
= 13.5, 8.5 Hz, 1H, CH2) 4.37–4.44 (m, 1H, CH) 4.67 (dd, J = 8.5, 7.0 
Hz, 1H, CH) 5.83 (dd, J = 15.0, 2.0 Hz, 1H, CH) 6.65 (dd, J = 15.0, 4.5 
Hz, 1H, CH) 7.08–7.21 (m, 5H, ArH) 7.44–7.49 (m, 1H, ArH) 7.52–7.62 
(m, 6H, ArH) 7.63–7.69 (m, 1H, ArH) 7.81 (d, J = 7.0 Hz, 2H, ArH) 7.84 
(d, J = 8.0 Hz, 2H, ArH) 7.91 (dd, J = 7.5, 2.0 Hz, 1H, ArH) 8.03 (d, J =
8.0 Hz, 1H, ArH) 8.08 (dd, J = 7.5, 1.5 Hz, 1H, ArH) 8.61 (d, J = 8.5 Hz, 
1H, ArH) ppm. Note: The three NH signals were not observed in the 1H NMR 
spectrum. However a very dilute CDCl3 1H NMR spectrum clearly shows the 
three NH signals. 13C NMR (100 MHz, CDCl3/CD3OD 3:2, CD3OD refer-
ence): δ = 22.6 (CH2) 29.1 (CH2) 33.3 (CH2) 38.3 (CH2) 42.6 (CH2) 49.8 
(CH) 56.4 (CH) 124.2 (q, JCF = 272.0 Hz, CF3) 124.6 (CH) 125.0 (CH) 
125.9 (q, JCF = 3.5 Hz, CH) 127.3 (CH) 127.6 (q, JCF = 32.0 Hz, C-CF3) 
127.7 (CH) 128.0 (CH) 128.4 (CH) 128.5 (CH) 128.6 (C) 129.1 (CH) 
129.5 (q, JCF = 2.0 Hz, CH) 129.6 (CH) 129.9 (CH) 130.2 (CH) 133.9 
(CH) 134.2 (CH) 134.6 (CH) 134.8 (C) 135.6 (C) 136.8 (C) 137.5 (C) 
140.5 (C) 146.5 (CH) 167.7 (CO) 172.2 (CO) ppm. 19F NMR (376 MHz, 
CDCl3/CD3OD 3:2): δ = -59.67 ppm. HRMS (ES+) C40H38N3O6NaS2F3 




Isonicotinic acid (5 mg, 0.04 mmol, 1.2 equiv.) was stirred with 
EDCI∙HCl (7 mg, 0.04 mmol, 1.1 equiv.) and HOBt⋅H2O (6 mg, 0.04 
mmol, 1.2 equiv.) in CH2Cl2 (1 mL) for 10 min. Ammonium salt 8 (23 
mg, 0.03 mmol, 1 equiv.) was then added followed by DIPEA (13 μL, 
0.07 mmol, 2.2 equiv.) and the reaction mixture was stirred overnight. 
Solvent was removed in vacuo to give the crude product. Purification by 
column chromatography (EtOAc) gave amide 22 (15 mg, 63%) as a 
white solid. M.p. = 84–88 ◦C. Rf = 0.2 (EtOAc). IR (film): νmax = 3279, 
3055, 2927, 2863, 1649, 1537, 1446, 1410, 1318, 1146, 1085 cm− 1. 1H 
NMR (400 MHz, CDCl3): δ = 1.21–1.57 (m, 6H, CH2) 2.71–2.80 (m, 1H, 
CH2) 2.85–2.96 (m, 1H, CH2) 3.21 (dd, J = 13.5, 7.5 Hz, 1H, CH2) 3.28 
(dd, J = 13.5, 7.5 Hz, 1H, CH2) 4.62–4.72 (m, 1H, CH) 4.87 (app. q, J =
7.5 Hz, 1H, CH) 5.60–5.66 (m, 1H, NH) 6.14 (dd, J = 15.0, 2.0 Hz, 1H, 
CH) 6.58 (d, J = 9.0 Hz, 1H, NH) 6.78 (dd, J = 15.0, 4.5 Hz, 1H, CH) 
7.15–7.28 (m, 5H, ArH) 7.48 (m, 9H, ArH + NH) 7.87 (d, J = 7.0 Hz, 2H, 
ArH) 7.94 (d, J = 7.5 Hz, 1H, ArH) 8.06 (d, J = 8.0 Hz, 1H, ArH) 8.12 
(dd, J = 7.5, 1.0 Hz, 1H, ArH) 8.56–8.73 (m, 3H, ArH) ppm. 13C NMR 
(100 MHz, CDCl3): δ = 21.1 (CH2) 27.5 (CH2) 32.9 (CH2) 37.4 (CH2) 
42.0 (CH2) 48.5 (CH) 55.7 (CH) 121.1 (CH) 124.2 (CH) 124.3 (CH) 
126.9 (CH) 127.3 (CH) 127.7 (CH) 128.0 (C) 128.3 (CH) 128.9 (CH) 
129.19 (CH) 129.23 (CH) 129.3 (CH) 129.4 (CH) 130.5 (CH) 133.6 (CH) 
134.3 (CH) 134.6 (C) 136.2 (2 × C) 140.0 (C) 140.2 (C) 145.3 (CH) 
150.6 (CH) 166.3 (CO) 171.2 (CO) ppm. HRMS (ES+) C38H38N4O6NaS2 




3,4-(Methylenedioxy)phenylacetic acid (12 mg, 0.06 mmol, 2 
equiv.) was stirred with EDCI∙HCl (11 mg, 0.06 mmol, 2 equiv.) and 
HOBt⋅H2O (10 mg, 0.06 mmol, 2 equiv.) in CH2Cl2 (1 mL) for 10 min. 
Ammonium salt 8 (20 mg, 0.03 mmol, 1 equiv.) was then added fol-
lowed by DIPEA (15 μL, 0.09 mmol, 3 equiv.) and the reaction mixture 
was stirred overnight. The reaction mixture was diluted with CH2Cl2 (10 
mL) and washed with 1 M HCl (5 mL), sat. aq. NaHCO3 (5 mL) and brine 
(5 mL). The organic layer was dried over MgSO4, filtered and solvent 
was removed in vacuo to give the crude product. Purification by column 
chromatography (c-Hex/EtOAc; 1:1) gave amide 23 (6 mg, 27%) as a 
white solid. M.p. = 58–62 ◦C. Rf = 0.3 (c-Hex/EtOAc; 1:1). IR (film): 
νmax = 3285, 3065, 2928, 1646, 1544, 1503, 1445, 1316, 1245, 1146, 
1086, 1038, 930, 738 cm− 1. 1H NMR (400 MHz, CDCl3): δ = 1.19–1.54 
(m, 6H, CH2) 2.72–2.82 (m, 1H, CH2) 2.90–3.04 (m, 2H, CH2) 3.09 (dd, 
J = 14.0, 7.5 Hz, 1H, CH2) 3.45 (d, J = 15.0 Hz, 1H, CH2) 3.50 (d, J =
15.0 Hz, 1H, CH2) 4.56–4.67 (m, 2H, CH) 5.66–5.71 (m, 1H, NH) 5.93 (s, 
2H, CH2) 6.04 (dd, J = 15.0, 1.5 Hz, 1H, CH) 6.38 (d, J = 9.0 Hz, 1H, 
NH) 6.60–6.67 (m, 3H, ArH) 6.70 (d, J = 8.0 Hz, 1H, NH) 6.73 (dd, J =
15.0, 4.5 Hz, 1H, CH) 7.09–7.13 (m, 2H, ArH) 7.16–7.23 (m, 3H, ArH) 
7.51–7.73 (m, 6H, ArH) 7.84 (d, J = 7.5 Hz, 2H, ArH) 7.94 (d, J = 8.0 
Hz, 1H, ArH) 8.07 (d, J = 8.5 Hz, 1H, ArH) 8.24 (d, J = 7.5 Hz, 1H, ArH) 
8.74 (d, J = 8.5 Hz, 1H, ArH) ppm. 13C NMR (100 MHz, CDCl3): δ = 21.1 
(CH2) 27.5 (CH2) 33.1 (CH2) 37.0 (CH2) 42.2 (CH2) 42.8 (CH2) 48.1 
(CH) 55.1 (CH) 101.0 (CH2) 108.5 (CH) 109.7 (CH) 122.6 (CH) 124.2 
(CH) 124.5 (CH) 126.9 (CH) 127.1 (CH) 127.7 (CH) 127.9 (C) 128.1 (C) 
128.3 (CH) 128.7 (CH) 129.1 (CH) 129.15 (CH) 129.3 (CH) 129.4 (CH) 
129.4 (CH) 130.3 (CH) 133.6 (CH) 134.2 (CH) 134.3 (C) 134.9 (C) 136.2 
(C) 140.0 (C) 145.4 (CH) 146.8 (C) 147.9 (C) 171.5 (CO) 172.4 (CO) 
ppm. HRMS (ES+) C41H41N3O8NaS2 (MNa+) calcd. 790.2233; found 
790.2212. [α]D = -26 (c = 0.1, CH2Cl2). 
5.14. (S)-2-Azido-N-((S,E)-7-(naphthalene-1-sulfonamido)-1- 
(phenylsulfonyl)hept-1-en-3-yl)-3-phenylpropanamide 25 
Ammonium salt 8 (81 mg, 0.12 mmol, 1 equiv.) was stirred with 
imidazole-1-sulfonyl azide hydrochloride salt 24 (106 mg, 0.51 mmol, 4 
equiv.) in MeOH (1 mL). K2CO3 (69 mg, 0.50 mmol, 4 equiv.) was added 
followed by CuSO4⋅5H2O (1 mg, 0.004 mmol, 0.03 equiv.) and the re-
action mixture was left to stir overnight at room temperature. Solvent 
was removed in vacuo to give a crude residue which was dissolved in 
EtOAc (20 mL), washed with water (2 × 10 mL), brine (10 mL), dried 
over MgSO4, filtered and solvent was removed in vacuo to give the crude 
product. Purification by column chromatography (c-Hex/EtOAc; 1:1) 
gave azide 25 (32 mg, 40%) as a white crystalline solid. M.p. =
55–60 ◦C. Rf = 0.3 (c-Hex/EtOAc; 1:1). IR (film): νmax = 3314, 2937, 
2114, 1712, 1670, 1526, 1447, 1309, 1182, 1147, 1085, 1005 cm− 1. 1H 
NMR (500 MHz, CDCl3): δ = 0.99–1.11 (m, 2H, CH2) 1.22–1.39 (m, 4H, 
CH2) 2.77–2.86 (m, 2H, CH2) 3.03 (dd, J = 14.0, 7.0 Hz, 1H, CH2) 3.22 
(dd, J = 14.0, 5.0 Hz, 1H, CH2) 4.16 (dd, J = 7.0, 5.0 Hz, 1H, CH) 
4.43–4.50 (m, 1H, CH) 5.02 (t, J = 6.0 Hz, 1H, NH) 6.20 (dd, J = 15.0, 
1.5 Hz, 1H, CH) 6.28 (d, J = 8.5 Hz, 1H, NH) 6.75 (dd, J = 15.0, 5.0 Hz, 
1H, CH) 7.12–7.25 (m, 5H, ArH) 7.53–7.58 (m, 3H, ArH) 7.59–7.69 (m, 
3H, ArH) 7.85 (d, J = 7.0 Hz, 2H, ArH) 7.96 (d, J = 8.0 Hz, 1H, ArH) 
8.08 (d, J = 8.0 Hz, 1H, ArH) 8.25 (dd, J = 7.5, 1.0 Hz, 1H, ArH) 8.65 (d, 
J = 8.0 Hz, 1H, ArH) ppm. 13C NMR (125 MHz, CDCl3): δ = 22.0 (CH2) 
28.8 (CH2) 32.9 (CH2) 38.0 (CH2) 42.5 (CH2) 49.2 (CH) 64.8 (CH) 124.2 
(CH) 124.3 (CH) 127.0 (CH) 127.3 (CH) 127.7 (CH) 128.1 (C) 128.4 
(CH) 128.6 (CH) 129.2 (CH) 129.4 (CH) 129.5 (CH) 129.7 (CH) 130.6 
(CH) 133.7 (CH) 134.3 (C) 134.4 (CH) 134.5 (C) 135.6 (C) 139.8 (C) 
145.1 (CH) 168.3 (CO) ppm. HRMS (ES+) C32H33N5O5NaS2 (MNa+) 
calcd. 654.1821; found 654.1812. [α]D = +41 (c = 0.1, CH2Cl2). 
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Azide 25 (10 mg, 0.02 mmol, 1 equiv.) was stirred with phenyl-
acetylene (3 μL, 0.03 mmol, 1.8 equiv.), CuSO4⋅5H2O (0.2 mg, 8 μmol, 
0.05 equiv, i.e. 20 μL of a 10 mg/mL stock solution in H2O) in CH2Cl2/ 
H2O; 1:1 (0.6 mL). Sodium ascorbate (1 mg, 0.005 mmol, 0.3 equiv.) was 
added and the reaction mixture was stirred vigourously for 24 h. The 
reaction mixture was diluted with CH2Cl2 (5 mL) and water (1 mL). The 
layers were separated and the aqueous layer was extracted with CH2Cl2 
(2 × 5 mL). The combined organic layers were washed with brine, dried 
over MgSO4, filtered and solvent was removed in vacuo. Purification by 
column chromatography (c-Hex/EtOAc; 1:1) gave triazole 26 (6 mg, 
52%) as a white solid. M.p. = 196–198 ◦C. Rf = 0.5 (c-Hex/EtOAc; 1:2). 
IR (film): νmax = 3346, 3208, 1677, 1528, 1446, 1316, 1260, 1202, 
1145, 1080, 947, 799, 752 cm− 1. 1H NMR (400 MHz, CDCl3/CD3OD 3:2, 
CD3OD reference): δ = 1.00–1.14 (m, 2H, CH2) 1.18–1.37 (m, 4H, CH2) 
2.64–2.78 (m, 2H, CH2) 3.27 (dd, J = 13.0, 6.5 Hz, 1H, CH2) 3.47 (dd, J 
= 13.0, 9.5 Hz, 1H, CH2) 4.28–4.35 (m, 1H, CH) 5.46 (dd, J = 9.5, 6.5 
Hz, 1H, CH) 5.73 (dd, J = 15.0, 1.5 Hz, 1H, CH) 6.60 (dd, J = 15.0, 4.5 
Hz, 1H, CH) 7.10–7.19 (m, 5H, ArH) 7.31 (t, J = 7.5 Hz, 1H, ArH) 7.37 
(d, J = 7.5 Hz, 2H, ArH) 7.39–7.41 (m, 1H, NH) 7.46 (t, J = 8.0 Hz, 1H, 
ArH) 7.51–7.68 (m, 6H, ArH) 7.74 (d, J = 7.0 Hz, 2H, ArH) 7.79 (d, J =
7.0 Hz, 2H, ArH) 7.89 (d, J = 8.5 Hz, 1H, ArH) 8.00 (d, J = 8.5 Hz, 1H, 
ArH) 8.11 (dd, J = 7.5, 1.0 Hz, 1H, ArH) 8.21 (s, 1H, ArH) 8.59 (d, J =
8.5 Hz, 1H, ArH) ppm. 13C NMR (100 MHz, CDCl3/CD3OD 3:2, CD3OD 
reference): δ = 22.5 (CH2) 29.0 (CH2) 33.1 (CH2) 39.2 (CH2) 42.4 (CH2) 
49.5 (CH) 65.1 (CH) 119.8 (CH) 124.4 (CH) 124.7 (CH) 125.9 (CH) 
127.1 (CH) 127.8 (CH) 128.0 (C) 128.4 (CH) 128.45 (CH) 128.8 (CH) 
129.1 (CH) 129.2 (CH) 129.3 (CH) 129.35 (CH) 129.5 (CH) 129.7 (CH) 
130.2 (CH) 130.3 (C) 134.1 (CH) 134.4 (CH) 134.6 (C) 135.0 (C) 135.2 
(C) 140.1 (C) 145.7 (CH) 148.2 (C) 167.8 (CO) ppm. HRMS (ES+) 
C40H39N5O5NaS2 (MNa+) calcd. 756.2290; found 756.2296. [α]D = -14 
(c = 0.1, EtOAc). 
5.16. (S)-2-(4-Hexyl-1H-1,2,3-triazol-1-yl)-N-((S,E)-7-(naphthalene-1- 
sulfonamido)-1-(phenylsulfonyl)hept-1-en-3-yl)-3-phenylpropanamide 27 
Azide 25 (10 mg, 0.02 mmol, 1 equiv.) was stirred with 1-octyne (3 
μL, 0.02 mmol, 1.3 equiv.), CuSO4⋅5H2O (0.2 mg, 8 μmol, 0.05 equiv, i.e. 
20 μL of a 10 mg/mL stock solution in H2O) in CH2Cl2/H2O; 1:1 (0.6 
mL). Sodium ascorbate (1 mg, 0.005 mmol, 0.3 equiv.) was added and 
the reaction mixture was stirred vigourously for 24 h. The reaction 
mixture was diluted with CH2Cl2 (5 mL) and water (1 mL). The layers 
were separated and the aqueous layer was extracted with CH2Cl2 (2 × 5 
mL). The combined organic layers were washed with brine, dried over 
MgSO4, filtered and solvent was removed in vacuo. Purification by col-
umn chromatography (c-Hex/EtOAc; 1:1) gave triazole 27 (6 mg, 51%) 
as a white solid. M.p. = 62–65 ◦C. Rf = 0.5 (c-Hex/EtOAc; 1:2). IR (film): 
νmax = 3310, 3053, 2928, 2857, 1678, 1546, 1447, 1317, 1201, 1146, 
1085 cm− 1. 1H NMR (400 MHz, CDCl3): δ = 0.87 (t, J = 6.5 Hz, 3H, CH3) 
1.10–1.48 (m, 12H, CH2) 1.53–1.64 (m, 2H, CH2) 2.63 (t, J = 7.5 Hz, 2H, 
CH2) 2.73–2.91 (m, 2H, CH2) 3.31 (dd, J = 13.5, 8.0 Hz, 1H, CH2) 3.51 
(dd, J = 13.5, 8.0 Hz, 1H, CH2) 4.43–4.52 (m, 1H, CH) 5.29–5.37 (m, 
2H, CH + NH) 5.95 (d, J = 15.0 Hz, 1H, CH) 6.68 (dd, J = 15.0, 5.0 Hz, 
1H, CH) 6.82 (d, J = 8.0 Hz, 1H, NH) 7.00–7.07 (m, 2H, ArH) 7.13–7.18 
(m, 3H, ArH) 7.39 (s, 1H, ArH) 7.51–7.68 (m, 6H, ArH) 7.82 (d, J = 7.5 
Hz, 2H, ArH) 7.94 (d, J = 8.0 Hz, 1H, ArH) 8.06 (d, J = 8.0 Hz, 1H, ArH) 
8.24 (d, J = 7.5 Hz, 1H, ArH) 8.67 (d, J = 8.5 Hz, 1H, ArH) ppm. 13C 
NMR (100 MHz, CDCl3): δ = 14.1 (CH3) 21.9 (CH2) 22.5 (CH2) 25.6 
(CH2) 28.6 (CH2) 28.8 (CH2) 29.2 (CH2) 31.5 (CH2) 32.7 (CH2) 39.2 
(CH2) 42.4 (CH2) 49.7 (CH) 65.6 (CH) 121.3 (CH) 124.2 (CH) 124.4 
(CH) 126.9 (CH) 127.5 (CH) 127.6 (CH) 128.1 (C) 128.4 (CH) 128.8 
(CH) 128.9 (CH) 129.1 (CH) 129.3 (CH) 129.7 (CH) 130.5 (CH) 133.6 
(CH) 134.3 (C, CH) 134.6 (C) 135.1 (C) 140.0 (C) 144.9 (CH) 148.6 (C) 
167.5 (CO) ppm. HRMS (ES+) C40H47N5O5NaS2 (MNa+) calcd. 
764.2916; found 764.2945. [α]D = -20 (c = 0.1, CH2Cl2). 
5.17. Trypanosome cell culture 
The bloodstream form Trypanosome brucei brucei MITat1.1 strain was 
used for assessment of compound sensitivity in vitro. As described,8 T. b. 
brucei was cultured in antibiotic-free HMI-9 medium supplemented with 
10% heat-inactivated fetal bovine serum (FBS) (Biosera, UK). Try-
panosomes were subcultured at the appropriate dilutions (1:10) every 
24 h in fresh HMI-9 medium to ensure log growth phase. The cultures 
were maintained in a humidified atmosphere containing 5% CO2 at 
37 ◦C. 
5.18. Trypanosomal viability assays 
The effect of each final compound in the series on parasite growth 
was determined using the Alamar Blue cell viability assay. This assay 
was performed in triplicate according to Räz et al.16 Briefly, T. b. brucei 
cells (strain MIT at 1.1) were seeded in 96-well plates at a density of 2 ×
105 cells/mL in 100 µL media in the presence of varying concentrations 
of predicted inhibitors (5 μM, 1 μM, 500 nm, 100 nM, 10 nM, 100 pM) or 
DMSO alone. A further 30 µL of media was added to each well. After 6 h, 
15 µL of Alamar Blue (Invitrogen) was added to the cells and incubation 
continued so that the total incubation time was 24 h. Absorbances at 540 
and 595 nm were measured using a SpectraMax M3 Microplate Reader 
(Molecular Devices), and EC50 values were calculated using the 
GraphPad Prism 8 software. 
5.19. HaCaT cell culture 
Human Skin Keratinocyte cell line HaCaT was used to assess the ef-
fects of cell proliferation and cytotoxicity of a range of compounds. 
Stocks were tested for mycoplasma contamination (Lonza MycoAlertTM 
LT07-218). 
5.20. Mammalian cell sub-culturing 
HaCaT cells were established in Dubecco’s Eagle Modified Media 
with L-glutamine (DMEM) with 10% fetal calf serum. Volumes used are 
for 75 cm2 flask; cell culture medium was removed and discarded (vir-
kon). Briefly, cell layers were gently rinsed with 0.25% (w/v) trypsin- 
0.53 mM EDTA solution to remove all traces of serum that contains 
trypsin inhibitor. Then 2.0 to 3.0 mL of trypsin-EDTA solution was 
added per flask and cells observed under an inverted microscope until 
cell layer is dispersed (usually within 5 to 15 min). Cells that are difficult 
to detach were placed at 37 ◦C to facilitate dispersal (cells were not 
agitated during the detachment process in order to avoid clumping). 
Thereafter, 6–8.0 mL of complete growth medium was added to 
neutralise the trypsin solution and cells were aspirated by gently 
pipetting. Appropriate aliquots of the cell suspension were added to new 
culture vessels with fresh media [A cell suspension, as described above, 
was prepared then resuspended in media after centrifugation and 
counted using haemocytometer to determine correct seeding densities]. 
Cultures were established between 2 × 103 and 1 × 104 viable cells/cm2 
and did not exceed 7 × 104 cells/cm2. All cells were incubated at 37 ◦C 
with 5% CO2 atmosphere and maintained at a cell confluence of between 
30% and 90%. Prior to testing compounds with MTT and LDH, com-
pounds were tested for cross reactivity to LDH and MTT reagents. No 
atypical reaction with compounds tested and assay reagents was 
evident. 
5.21. LDH assay 
The LDH assay,18 quantitatively measuring lactate dehydrogenase 
(LDH) released into the media from damaged cells, assesses the number 
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of cells undergoing apoptosis, necrosis, and other forms of cellular 
damage. LDH assay was carried out using the Peirce LDH Cytotoxicity 
Kit (Thermo Scientific #88954), according to manufacturer’s specifi-
cations. In brief, for LDH analysis 50 µL of transferred media after cell 
treatment was added to 50 µL of reaction buffer (1:1 ratio) in a flat- 
bottomed plate and incubated at room temperature in the dark for 30 
min. After the incubation time 50 µL of stop buffer was added and the 
absorbance was read at 490 nm and 680 nm. Results were normalised to 
negative untreated (spontaneous LDH release) and positive 10X Lysis 
Buffer (maximum LDH release) in order to report a % cytotoxicity. 
Statistical analysis was carried out using GraphPad Prism 8, results were 
normalised to positive and negative controls and nonlinear regression 
was carried out on MTT results using log(inhibitor) vs normalised 
response. To ensure statistical validity, cell assays were repeated in 
triplicate, i.e. three times on different days with different cell stocks with 
similar passage numbers. 
5.22. MTT assay 
The MTT assay, performed as described by Mosmann,19 was used to 
assess the viability of cells post-treatment with all compounds in the 
series. MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) a yellow tetrazole is readily incorporated by viable cells and 
reduced by the mitochondrial enzyme succinate dehydrogenase to form 
the insoluble purple coloured formazan compound. Viability, connected 
with the quantification of formazan, was measured by absorbance be-
tween 520 and 600 nm. For all MTT assays, 100 μL of cells in media were 
seeded per well (1x105 cells/mL) in a 96 well plate and incubated for 24 
h. After the 24 h the media was gently removed and cells were washed 3 
times with sterile PBS, being careful not disrupt the cell monolayer. Drug 
compounds were provided at 10 mM in DMSO, and were diluted to 100 
µM in DMEM complete media and sterile filtered using a 0.22 μm filter, 
next samples were incubated in triplicate wells with positive (0.1% v/v 
Triton-X100 in PBS), and negative (untreated) controls included in each 
plate. Following 24 h exposure to all solutions, media was removed and 
50 µL added to a new 96 well plate for use in the LDH assay if required. 
Then 100 µL of MTT solution (0.5 mg/mL MTT in complete media) was 
next added to each well without washing, or disturbing the cell mono-
layer, and incubated for 3 h. The MTT solution was carefully removed 
without disturbing any crystals that formed and 100 μL DMSO was 
added to each well to solubilise the formazan crystals. The plate was 
transferred to an orbital shaker which was shaken for 15 mins. Absor-
bance was then measured at 590 nm on a ThermoScientific Multiskan 
GO plate reader. 
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